<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=213807269037206&amp;ev=PageView&amp;noscript=1">
Compliance In Focus
Posted by John Lehmann on Thu, Sep 27, 2018

Don’t Make These Mistakes In Your Clinical Trial: The Most Common FDA Violations

The FDA’s Bioresearch Monitoring (BIMO) inspection program ensures the protection of the rights, safety and welfare of human subjects during clinical research trials. FDA-warning-letters

The most recent results represent findings from more than 1,300 clinical research audits of clinical investigators, sponsors and IRBs for the 2017 fiscal year.

This whitepaper covers the seven most common ones and how you can avoid them.

 2017 FDA Inspections Blog CTA

Topics: FDA Warning Letters


Posts by Topic: